scholarly journals CHRONIC PERSISTENT ASTHMA

2018 ◽  
Vol 25 (07) ◽  
pp. 1094-1101
Author(s):  
Syed Saud Hasan ◽  
Moosa Khan ◽  
Musarrat Sultana ◽  
Muhammad Talha Farooqui ◽  
Asif Iqbal
Keyword(s):  
Safety Profile ◽  
Seed Oil ◽  
Persistent Asthma ◽  
Inflammatory Disorder ◽  
Night Sleep ◽  
Interventional Study ◽  
Once Daily ◽  
Chronic Inflammatory Disorder ◽  
Group B

Asthma, a chronic inflammatory disorder, prevalence is high in all ages,characterizes by cough, dyspnea, chest compression, wheezing and considerable impairmentin physical activities. Study Design: An interventional study. Objectives: Observe improvementin pulmonary functions, symptoms& quality of daily life with safety profile in chronic moderatepersistent asthma. Place & Duration: Approved with BASR University of Karachi and conductedwith the participation BMSI (Pharmacology), JPMC & Eastern Medicine HMU, Karachi. Method& Materials: Total 120 diagnosed with objective signs of reversibility, by measuring at least12% increase in FEV1, after 15 minutes with an inhalation of 200 microgram (μg) Salbutamol ofasthmatic patients were registered & divided in two groups.Group-A treated with oral Borage1.3 gram once plus Echium seed oil 500mg twice daily & Group B treated with Borage 1.3 gramonce plus Echium seed oil 500mg twice along with oral Bambuterol 10mg once daily for 90days, results of Spirometry, PEFR, daily dairy symptoms card and clinical questionnaire werestatistically evaluated, to estimate the improvement and compliance of the drugs. Results:Borage & Echium treated groups from baseline to day-90, FEV1 mean 1.30+0.02 (L) change of4.7%, FVC mean 2.3+0.3 increase of 2.19%, PEFR mean 186.3+34.1 (L/mints) change 4.1%.In group-B, FEV1 mean 1.5+0.3 increase of 13.3%, FVC mean 2.5+0.4 increase of 9.2%, PEFRmean 215.8+50.3, change of 15.2%, results are highly significant. Symptoms of daily dairycard in both group shows improvement, and reduction in night sleep awakening and clinicalquestionnaire shows improved symptoms, decreased need of recue medicine at day-90.Conclusion: Combination therapy, provided synergistic effect, to reduce the severity, improvesymptoms, quality of life along with the safety profile, results are highly significant.

scholarly journals Prevalence and impact of allergic rhinitis in school going children

2021 ◽  
Vol 7 (5) ◽  
pp. 760
Author(s):  
Sucheta Gupta ◽  
Vinod Gupta ◽  
Akhil Gupta
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Negative Impact ◽  
Community Health Center ◽  
Medical Intervention ◽  
House Dust Mites ◽  
Inflammatory Disorder ◽  
Chronic Inflammatory Disorder ◽  
Co Morbidity

<p><strong>Background:</strong> Allergic rhinitis (AR) is a chronic inflammatory disorder affecting the nasal mucosa. There is negative impact of AR on several aspects of day to day living and quality of life (QoL), which include: daily functioning, sleep, absenteeism, school productivity and academic performance. Almost 40% of children are being affected by AR.</p><p><strong>Method:</strong> An observational study was conducted on randomly selected 100 parents of school going children aging 2 to 15 years, attending OPD in community health center, Chenani, district Udhampur, J and K, for a period of one year from June 2018 to Nov 2018. Children having frequent episodes of allergic rhinitis were enquired about their history of sneezing, runner itchy nose and eyes, thick mucus, nasal blockage or breathless with associated symptoms were selected.</p><p><strong>Results:</strong> 81% of subjects had a worse problem during specific months of the year; and 67% had itchy-watery eyes. In 15% of subjects, AR impacted daily activities. A prevalence of 28% for nasal symptoms and 14% for allergic rhino-conjunctivitis was found. Study also showed significantly higher proportion of blockers (61%) than sneeze runners (39%). 56% children had one or more co morbidity, whereas 44% had ‘nil’ co-morbidities. The most common allergens were: pollens (grass, trees and weeds), house dust mites, pets, molds, fungi and food.</p><p><strong>Conclusions:</strong> AR adversely affects quality of life of patients and furthermore studies should be conducted for more clarity on the subject, besides a timely medical intervention and treatment could possibly avoid the rising morbidity associated with the disease.</p>

scholarly journals Observation of the Improvement in Nocturnal Asthma Symptoms with Administration of Once Daily Sustained Released Theophylline

2018 ◽  
Vol 9 (2) ◽  
pp. 74-77
Author(s):  
Mesbahul Karim Ruble ◽  
AKM Rafiqul Bari ◽  
Amar Biswas ◽  
Md Khairul Anam ◽  
Mahbub E Khuda ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sustained Release ◽  
Pulmonary Function Tests ◽  
Persistent Asthma ◽  
Nocturnal Asthma ◽  
Once Daily ◽  
Asthma Symptoms ◽  
Sustained Release Theophylline

Objective: The aims and objective of this study to observe the improvement in Nocturnal Asthma symptoms and Quality of Life (QoL) with administration of once daily sustained release theophylline preparation.Background: Nocturnal symptoms are a common part of the asthma. Nocturnal asthma is defined by a drop in forced expiratory volume in 1 second (FEV1) of at least 15% between bedtime and awakening in patients with clinical and physiologic evidence of asthma, which may include improvement in QoL.Methodology: The patient with Chronic Persistent Asthma, both sex, age >18 to 50 years of age and preferably patients with nocturnal exacerbations were included in the study. All patients were diagnosed on the basis of clinical history, physical examination, chest X-ray and pulmonary function tests, in accordance with the clinical criteria for the diagnosis by the GINA. The recruitment period was between March 2017 and August 2017 Shaheed Suhrawardy Medical College Hospital, Dhaka.Results: It was observed that 65(92.85%) was found exacerbation free night and 5(7.15%) patients were found exacerbation with sustained release Theophylline. There are significantly improved qualities of life between 1st follow up to 2nd follow up, 3rd follow up and 4th follow up p<0.001 which was statistically significant. Spirometry test was gradually improved between 1st visit of FEV1 to 2nd, 3rd and 4th visit of FEV1, (p<0.001) that was statistically significant.Conclusion: Most of the patients were found exacerbation free night. There are significantly improved quality of life between 1st follow up to 2nd follow up, 3rd follow up and 4th follow up in Spirometry test. The value of FEV1 was gradually improve in the lst visit, 2nd, 3rd and 4th visit with sustained release Theophylline.J Shaheed Suhrawardy Med Coll, December 2017, Vol.9(2); 74-77

Factors affecting asthma psychomorbidity, control and illness-related quality of life: what is the interaction?

2011 ◽  
Vol 26 (S2) ◽  
pp. 1745-1745
Author(s):  
N. Pilipenko ◽  
M. Karekla
Keyword(s):  
Quality Of Life ◽  
Asthma Control ◽  
Research Literature ◽  
Smoking History ◽  
Inflammatory Disorder ◽  
Chronic Inflammatory Disorder ◽  
Asthma Patients ◽  
Related Quality ◽  
The Impact

Asthma is a chronic inflammatory disorder of the airways, ounknown etiology and growing prevalence (GINA, 2009). Appropriate asthma management can control the disorder and enable patients to enjoy a good quality of life (WHO, 2007).Yet, many asthma patients are unable to maintain asthma control (Rabe et al., 2003) for various reasons, including psychological ones (Feldman et al., 2005).This study examined the prevalence of psychomorbidity, and its interaction with asthma control difficulties and asthma-related quality of life in a sample of 200 asthma patients in Cyprus. Asthma diagnoses and severity were established by medical chart review.Psychomorbidity was evaluated using the Patient Health Questionnaire (Spitzer, 1999). Additionally, the impact of asthma-specific (e.g. asthma knowledge), health-specific (e.g. smoking history) and socio-demographic (e.g. perceived poverty) factors was examined as prior research literature suggests these may significantly impact asthma control and asthma-related quality of life.Currently, the present study is in its final stages of data collection (to conclude 2010). The results will offer valuable insights into the mechanisms and factors which affect asthma control, quality of life, and psychomorbidity. In doing so, the present study will contribute to the improved understanding of asthma patients’ experiences, essential to guide medical and psychological interventions.

Classification of asthma

2019 ◽  
Vol 40 (6) ◽  
pp. 385-388 ◽  
Author(s):  
Nurcicek Padem ◽  
Carol Saltoun
Keyword(s):  
Immunoglobulin E ◽  
Persistent Asthma ◽  
Acid Reflux ◽  
Lung Mechanics ◽  
Inflammatory Disorder ◽  
Upper Respiratory Tract ◽  
Cough Variant Asthma ◽  
Chronic Inflammatory Disorder ◽  
Tract Infections ◽  
Underlying Pathophysiology

Asthma is a chronic inflammatory disorder of the airways that results, physiologically, in hyperreactivity and, clinically, in recurrent episodes of wheezing, chest tightness, or coughing. Airway inflammation, smooth-muscle contraction, epithelial sloughing, mucous hypersecretion, bronchial hyperresponsiveness, and mucosal edema contribute to the underlying pathophysiology of asthma. Diagnostic tests such as methacholine or mannitol challenges or spirometry (pre- and postbronchodilator responses) help to identify such underlying pathophysiology via assessments of bronchial hyperreactivity and lung mechanics but are imperfect and, ultimately, must be viewed in the context of a patient's clinical presentation, including response to pharmacotherapy. Asthma can be classified into either intermittent or persistent, and the latter is either mild, moderate, or severe. Some patients change, in either direction, from intermittent to persistent asthma. In addition, patients with asthma may be classified as allergic (immunoglobulin E mediated), nonallergic (often triggered by viral upper respiratory tract infections or no apparent cause), occupational, aspirin-exacerbated respiratory disease, potentially fatal, exercise-induced, and cough variant asthma. In the latter, the patients have a nonproductive cough that responds to treatment for asthma but not with antibiotics, expectorants, mucolytics, antitussives, or beta2-adrenergic agonists, and to treatment for acid reflux and rhinosinusitis. Thus, cough variant asthma is in the differential diagnosis of chronic cough.

Effectiveness of Montelukast versus Budesonide on Quality of Life and Bronchial Reactivity in Subjects with Mild-Persistent Asthma

2002 ◽  
Vol 15 (2) ◽  
pp. 149-155 ◽  
Author(s):  
G. Riccioni ◽  
E. Ballone ◽  
N. D'Orazio ◽  
S. Sensi ◽  
M. di Nicola ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inhaled Corticosteroids ◽  
Challenge Test ◽  
Persistent Asthma ◽  
Wilcoxon Test ◽  
Bronchial Reactivity ◽  
Treatment Groups ◽  
Mild Persistent Asthma ◽  
Group B

Insufficient data exist to evaluate the comparative effects of inhaled corticosteroids (ICS) versus leukotriene receptor antagonist (LTRA) on airway inflammation and quality of life (QoL). The aim of the study was to compare the effectiveness of montelukast compared to budesonide at different doses on QoL and bronchial reactivity in mild-asthmatic adult patients. 45 subjects with bronchial asthma were randomly assigned to a different treatment and divided in 3 treatment groups: A: 400 μg of budesonide twice a day; B: 10 mg of montelukast daily; C: 10 mg of montelukast daily plus 400 μg of budesonide twice a day. At the beginning of the study and at the end of the treatment period (16 weeks) all patients underwent complete clinical evaluation, pulmonary function testing and methacholine challenge test (MCHt). In group A the increase from baseline was 153.4%, in group C was 133.2%, and in group B 247.7%, the latter increase being statistically significant compared to that in the other 2 groups (p< 0.005 Wilcoxon test). In all domains the improvement in quality of life in the group treated with montelukast (group B) was significantly greater than that in the group treated with both medications (group C): in particular, the improvement was consistent in the symptoms (p< 0.01) and emotions (p< 0.01) domains, and weaker in the physical activity (p< 0.05). A similar difference was observed between group B and A, but only in the symptoms (p<0.01), emotions (p<0.01), and environmental stimuli domains (p<0.05). The personal perception of their own disease is important for a correct therapeutic management of asthma. In order to optimize the treatment, a complete adherence of the patient to the treatment itself is required, to be achieved through simplification of therapeutic schedule and easy administration of medications. Montelukast may be considered a valid alternative in the treatment of mild-persistent asthma, both for the clinical and functional benefits and for the great advantage of the once-daily dosage, which consistently improves the compliance with the chronic treatment of the disease.

Joint Ventures: Helping Those With Rheumatoid Arthritis Live Well

2013 ◽  
Vol 23 (2) ◽  
pp. 91-100 ◽  
Author(s):  
Aggie Stewart
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Stress Reduction ◽  
Symptom Relief ◽  
Well Being ◽  
Inflammatory Disorder ◽  
Yoga Therapy ◽  
Chronic Inflammatory Disorder ◽  
Stiffness Loss

Objectives: Rheumatoid arthritis (RA) is an autoimmune, chronic inflammatory disorder that causes pain, swelling, stiffness, loss of joint function, and reduced quality of life. Yoga therapy may help individuals with RA manage stress and increase well-being. This study focused on the identification of therapeutic objectives and a methodology to achieve symptom relief, regain function, and enhance quality of life for individuals with RA. Methods: Four women with RA participated in private yoga therapy sessions for 2.5 months. Assessment based, tailored home practices were developed and modified to address participant - identified goals. Results: Participants reported decreased pain, fatigue, swelling, and flares; increased energy; pain-free range of motion and strength around affected joints; and a heightened sense of well-being. Conclusions: Tailored yoga therapy that emphasizes stress reduction may be beneficial for individuals with RA.

scholarly journals Mesenchymal Stromal Cell Therapy in the Management of Perianal Fistulas in Crohn’s Disease: An Up-To-Date Review

Medicina ◽  
2020 ◽  
Vol 56 (11) ◽  
pp. 563
Author(s):  
Gaetano Gallo ◽  
Vincenzo Tiesi ◽  
Serena Fulginiti ◽  
Gilda De Paola ◽  
Giuseppina Vescio ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Stromal Cells ◽  
Tissue Repair ◽  
Negative Impact ◽  
Inflammatory Disorder ◽  
Chronic Inflammatory Disorder ◽  
Entire Gastrointestinal Tract

Crohn’s Disease (CD) is a chronic inflammatory disorder that potentially involves the entire gastrointestinal tract. Perianal fistulizing CD (pCD) is a serious and frequent complication associated with significant morbidities and a heavy negative impact on quality of life. The aim of CD treatment is to induce and maintain disease remission and to promote mucosal repair. Unfortunately, even the best therapeutic regimens in pCD do not have long-term efficacy and cause a significant number of side effects. Therefore, it is mandatory to study new therapeutical options such as the use of mesenchymal stromal cells (MSCs). These cells promote tissue repair via the induction of immunomodulation. The present review aims to analyze the existing updated scientific literature on MSCs adoption in the treatment of pCD to evaluate its efficacy and safety and to compare the use of bone marrow and adipose tissue derived MSCs, type of administration, and dose required for recovery.

scholarly journals Effectiveness and Quality of Life with Montelukast in Asthma – A double-blind randomized control trial

2019 ◽  
Vol 35 (3) ◽  
Author(s):  
Mirza Saif Ullah Baig ◽  
Rashid Ahmed Khan ◽  
Kamran Khan ◽  
Nadeem Rizvi
Keyword(s):  
Quality Of Life ◽  
Placebo Group ◽  
Asthma Control ◽  
Persistent Asthma ◽  
Double Blind ◽  
Once Daily ◽  
The Mean ◽  
Moderate Persistent Asthma

Objective: To determine the role of montelukast – a leukotriene receptor antagonist (LTRA) – in improving the quality of life (QOL) and asthma control of adult patients with mild to moderate persistent asthma. Methods: Randomized, double-blind, placebo-controlled, non-crossover trial was conducted from March 2017 till November 2018 in three hospitals of Karachi and Hyderabad. Adults of age 15 years or more with mild to moderate persistent asthma. Treatment group was administered tablet montelukast 10mg once daily; the other group was given a similar looking placebo; as an adjuvant to the current medication. QOL was assessed with Asthma Quality of Life Questionnaire – Standard (AQLQ-S) before and after the treatment. Asthma control was monitored via Asthma Control Test (ACT). Results: After 4 weeks, the mean ± SD of overall QOL on AQLQ-S improved from 3.74±0.88 to 5.06±0.89 for montelukast group and from 3.58±0.92 to 4.71±0.97 for placebo group (p=0.02). The improvement in sub-domains of symptoms, activity, and emotional functions was not significant; however, the sub-domain “environmental stimuli” significantly improved with 5.06±0.89 for montelukast group and 4.71±0.97 for placebo group (p=0.02). The mean ± SD of ACT, after four weeks, for montelukast group was 18.19±2.91 and for placebo group 17.28±3.36. Only on ACT, Montelukast did not show any statistically insignificant results. Conclusion: The role of montelukast in improving QOL of adult patients with mild to moderate persistent asthma is quite beneficial. It improves patient quality of life. It has the ease of once daily oral administration and also eradicates side effects associated with long-term adherence to steroids. doi: https://doi.org/10.12669/pjms.35.3.42 How to cite this:Baig S, Khan RA, Khan K, Rizvi N. Effectiveness and Quality of Life with Montelukast in Asthma – A double-blind randomized control trial. Pak J Med Sci. 2019;35(3):---------. doi: https://doi.org/10.12669/pjms.35.3.42 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals A Case Report: The Effect of Thread Embedding Acupuncture on Partly-Controlled Asthma

2021 ◽  
Vol 7 (2) ◽  
pp. 104
Author(s):  
Yusuf Gunawan ◽  
Irma Nareswari ◽  
Irma Nareswari
Keyword(s):  
Case Report ◽  
Inflammatory Process ◽  
Complementary Therapies ◽  
Inflammatory Disorder ◽  
Control Test ◽  
Uncontrolled Asthma ◽  
Asthma Control Test ◽  
Chronic Inflammatory Disorder ◽  
Anti Inflammation

Asthma is a chronic inflammatory disorder of the respiratory tract where many cells and cellular elements play a role, especially eosinophils, IgE, and other components. Uncontrolled asthma causes the quality of the patient's life to decline. Acupuncture is one of the complementary therapies that are scientifically proven to help cure asthma. Many studies have proven that acupuncture plays a role in the anti-inflammatory process. In this case report, we used the acupuncture method of thread embedding penetration from point EX-B1 to BL13, LI11, ST36, and BL23 on both sides. Acupuncture therapy is done once when the patient first arrives. The results after 3 months observations showed that patients experienced an improvement in eosinophil count, decreased level of IgE, and increased Asthma Control Test values. The improvement showed patients were fully controlled in the first month until the end of the evaluation. Therefore, thread embedding could be a good, safe, and effective treatment for asthma in adults.Keywords: asthma, thread embedding acupuncture, anti-inflammation

Sign in / Sign up

Export Citation Format

Share Document